# info@crystallizationsummit.com

Blog Standard

Simulation Aided Process/Product Development, Scale-up, Tech-Transfer, and Regulatory Submission

By Dr. Nima Yazdanpanah, Consultant, Procegence Mechanistic modelling and process simulation, based on first-principle analysis, is a well-practiced tool in the chemical industry. The diverse applications have been enabled...

Dr. San Kiang, J-Star Research / Porton

Currently Chief Technology Officer at Porton Pharmatech/J-Star Research, Inc. San Kiang is an SME in continuous processing API, continuous processing DP, particle engineering, pharmaceutical composite material, co-processing and pharmaceutical...

Enabling Technologies for Tox/FIH Formulation

By Dr. San Kiang, J-Star Research / Porton The business goal of most CMC development is to reach FIH as fast as possible. However, before IND or Phase 1,...

Novel analytical methods and insights into Amorphous Solid Dispersions

By Dr. Simon Bates, Rigaku Americas Corp X-ray powder diffraction has been the gold standard for solid state pharmaceutical analysis for quite some time. However, when it comes to...

Dr. Simon Bates, Rigaku Americas Corp

Dr. Simon Bates is currently V.P. of Science and Technology at Rigaku Americas Corp., where he nurtures collaborative relationships between industry partners and academia in the discovery of new...

Dr. Bob Docherty, Pfizer

Dr. Robert Docherty did his degree and PhD. at Strathclyde University and joined ICI/Zeneca in 1988 where he worked on the solid-state structure and crystallization of dyes, pigments, biocides,...

Digitally Enabled Workflows: Accelerating the Molecule to Medicine Journey

By Dr. Bob Docherty, Pfizer The focus would be on solid form screen & selection, crystallization process development, pre-formulation evaluations, particle engineering and projecting the API attributes to drug...

Dr. Ahmad Sheikh, AbbVie

Dr. Ahmad Sheikh, Head of Solid State & Comp.Chem., AbbVie   Ahmad Sheikh is Senior Research Fellow and Head of Solid-State Chemistry at AbbVie. He has over 20 years...

Reducing or Managing Complexity- New realities with emerging chemical space for small molecule developability

By Dr. Ahmad Sheikh, AbbVie   While new chemical entities represent majority of the drugs approved in the last five years, the diversity and complexity of these molecules continue...

Control, is it achievable in amorphous or poorly crystalline peptide isolations?

By Dr. Jeremy M. Merritt, Eli Lilly and Co. Abstract: pending

RSS
Follow by Email
LinkedIn
Share